Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications
Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma.
Journal: Blood advances
Published: July 10, 2020
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
Journal: American journal of hematology
Published: December 06, 2019
Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 12, 2018
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 05, 2017
E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 29, 2016
Showing 1-5 of 5
Last Updated: 09/26/2026